Publications

Publications from KolGoTRG Since 2020

  1. Manchanda R, Sun L, Patel S, Evans O, Wilschut J, De Freitas Lopes AC, et al. Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems. Cancers. 2020 Jul 17;12(7):1929. https://doi.org/10.3390/cancers12071929
  2. Kurtz J-E, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, et al. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecologic oncology. 2021 May 1;161(2):502–7. https://doi.org/10.1016/j.ygyno.2021.02.018
  3. Sengupta D, Ali SN, Bhattacharya A, Mustafi J, Mukhopadhyay A, Sengupta K. A deep hybrid learning pipeline for accurate diagnosis of ovarian cancer based on nuclear morphology. PLOS ONE. 2022 Jan 7;17(1):e0261181. https://doi.org/10.1371/journal.pone.0261181
  4. Shyam Sundar, Cummins C, Kumar S, Long J, Arora V, Janos Balega, et al. Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER‐2 cohort study. An International Journal of Obstetrics & Gynaecology. 2022 Jan 10;129(7):1122–32. https://doi.org/10.1111/1471-0528.17041
  5. Smith HL, Willmore E, Mukhopadhyay A, Drew Y, Curtin NJ. Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling. Cancers [Internet]. 2022 Jan 1 [cited 2023 Jul 4];14(22):5559. https://doi.org/10.3390/cancers14225559
  6. Datta SS, Fraser L, Burnell M, Nasreen S, Ghosh M, Ojha A, et al. Association of adult attachment with delays in accessing specialist care in women with ovarian cancer. Journal of Psychosocial Oncology. 2022 Feb 3;40(4):491–505. https://doi.org/10.1080/07347332.2022.2025510
  7. Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet [Internet]. 2022 Apr 9;399(10333):1412–28. https://doi.org/10.1016/S0140-6736(22)00323-3
  8. Chowdhury S, Kar A, Bhowmik D, Gautam A, Basak D, Sarkar I, et al. Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells. Cancer Research. 2022 May 31;82(14):2640–55. https://doi.org/10.1158/0008-5472.can-21-4052
  9. Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz J-E, et al. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. The Lancet Oncology [Internet]. 2022 Aug 1;23(8):e374–84. https://doi.org/10.1016/S1470-2045(22)00139-5
  10. Saha S, Rundle S, Kotsopoulos IC, Begbie J, Howarth R, Pappworth IY, et al. Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy. Cancers. 2022 Sep 1;14(17):4288–8. https://doi.org/10.3390/cancers14174288
  11. Manisha Vernekar, Chatterjee P, Bose S, Mandal A, Mandal R, Mukhopadhyay A. EP092/#966 The clinical implications and impact of hydronephrosis in cervical cancer at regional cancer centre in Eastern India. E-Posters. 2022 Dec 1; https://doi.org/10.1136/ijgc-2022-igcs.183
  12. Reid F, Mackay C, Lau I, Noll F, Nasser S, Basel Refky, et al. O022/#296 The equity challenges of a large-scale ovarian cancer patient experience study in low- and middle-income countries: the every woman study. 2022 Dec 1; https://doi.org/10.1136/ijgc-2022-igcs.24
  13. Sengupta D, Mukhopadhyay A, Sengupta K. Elevated Levels of Lamin A Promote HR and NHEJ-Mediated Repair Mechanisms in High-Grade Ovarian Serous Carcinoma Cell Line. Cells [Internet]. 2023 Jan 1 [cited 2023 Mar 9];12(5):757. https://doi.org/10.3390/cells12050757
  14. Elias K, Smyczynska U, Stawiski K, Nowicka Z, Webber J, Kaplan J, et al. Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles. Nature Communications [Internet]. 2023 Jun 8;14(1):3350. https://doi.org/10.1038/s41467-023-38925-4
  15. Ghosh DD, RoyChowdhury R, Dutta R, Mukhopadhyay I, Mukhopadhyay A, Roychoudhury S. In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries. Gynecologic oncology reports. 2023 Jun 1;47:101209–9. https://doi.org/10.1016/j.gore.2023.101209
  16. Ghosh A, Ghosh A, Sinha A, Mathai S, Bhaumik J, Mukhopadhyay A, et al. Identification of HPV16 positive cervical cancer subsets characterized by divergent immune and oncogenic phenotypes with potential implications for immunotherapy. Tumor biology. 2023 Aug 14;45(1):55–69. https://doi.org/10.3233/tub-220035
  17. Jayraj A, Nejati S, Mansy T, Mukhopadhyay A. PR059/#861 From phenotype to genotype: peroperative prediction of HRD status in epithelial ovarian cancers (EOC) based on serum CA-125, intraoperative tumour characteristics and surgical resectability. 2023 Nov 1; https://doi.org/10.1136/ijgc-2023-igcs.99
  18. Ghosh A, Sinha A, Ghosh A, Roy S, Mallick S, Kumar V, et al. Prognostic relevance of correlated co-expression of coding and noncoding RNAs in cervical cancers. bioRxiv (Cold Spring Harbor Laboratory). 2023 Dec 29; https://doi.org/10.1101/2023.12.28.573593
  19. Lakhiani A, Cummins C, Kumar S, Long J, Arora V, Janos Balega, et al. Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer—Quality of Life Evaluation Research) Prospective, International, Multicentre Study. Cancers. 2023 Dec 22;16(1):75–5. https://doi.org/10.3390/cancers16010075
  20. Goswami J, Pal AR, Barman SM, Sarkar A, Patro V, Bhowmik J, et al. Restrictive versus goal-directed fluid replacement strategy in ovarian cancer cytoreductive surgery (RiGoROCS): A randomised controlled trial. Indian Journal of Anaesthesia/Indian journal of anaesthesia. 2023 Dec 1;67(12):1101–9. https://doi.org/10.4103/ija.ija_489_23
  21. Yun BS, Lee K-B, Lee KH, Chang HK, Kim J-Y, Lim MC, et al. Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial). Journal of gynecologic oncology. 2024 Jan 1;35. https://doi.org/10.3802/jgo.2024.35.e57
  22. Mc Cormack M, Rincon DG, Eminowicz G, Diez P, Farrelly L, Kent C, et al. 154 A randomized phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial. 2024 Mar 1; https://doi.org/10.1136/ijgc-2024-esgo.2
  23. Sinha A, Ghosh A, Ghosh A, Mathai S, Bhaumik J, Mukhopadhyay A, et al. MAL expression downregulation through suppressive H3K27me3 marks at the promoter in HPV16-related cervical cancers is prognostically relevant and manifested by the interplay of novel MAL antisense long noncoding RNA AC103563.8, E7 oncoprotein and EZH2. Clinical epigenetics. 2024 Mar 10;16(1). https://doi.org/10.1186/s13148-024-01651-9
  24. Kar A, Ghosh P, Gautam A, Chowdhury S, Basak D, Sarkar I, et al. CD38–RyR2 axis–mediated signaling impedes CD8 + T cell response to anti-PD1 therapy in cancer. Proceedings of the National Academy of Sciences of the United States of America. 2024 Mar 7;121(11). https://doi.org/10.1073/pnas.2315989121

Publications from KolGOTRG as corresponding author.

  1. Mukhopadhyay A. EP365/#1142 Implementation of novel, alternative and affordable options for ovarian cancer care throughout the entire journey: a KolGo Trg approach. E-Posters. 2022 Dec 1; DOI: http://10.1136/ijgc-2022-igcs.454
  2. Mukhopadhyay A. EP385/#1176 Implementation of a modified medial inguinofemoral groin dissection technique to reduce morbidity in vulval cancer surgery: an UK- India experience. E-Posters. 2022 Dec 1; DOI: https://doi.org/10.1136/ijgc-2022-igcs.474
  3. Mukhopadhyay A, Ghosh T, Bhattacharjee D, Chakraborty D, Gupta R, Roychowdhury I, et al. EP290/#820 Intermittent PARP inhibitor regimen in ovarian cancer (IPIROC): origin and feasibility of implementing a proof-of-concept exploratory study. 2023 Nov 1; DOI: https://doi.org/10.1136/ijgc-2023-IGCS.357
  4. Chakraborty D, Mukhopadhyay A, Singhal S, Singh N, Pariyar J, Singh P, et al. EP209/#654 NuGenA (Nurse-led genetic counselling and awareness): a provider survey on barriers of implementation in LMICS. 2023 Nov 1; DOI: https://doi.org/10.1136/ijgc-2023-IGCS.291